Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort

Table 2

Univariable and Multivariable hazard ratios for clinical factors from the Cox regression analysis for the risk of PSA-failure.

Clinical factor	Number of men	Number of events	Univariable analysis		Multivariable analysis
			HR (95% CI)	𝑃 value	AHR (95% CI)	𝑃 value
Age at diagnosis (years)	357	34	0.99 (0.95, 1.04)	0.814	0.98 (0.92, 1.05)	0.542
PSA (ng/mL)	357	34	1.09 (1.04, 1.15)	0.001	1.09 (1.03, 1.16)	0.005
PPB (%)	357	34	1.04 (1.02, 1.06)	<0.001	1.03 (1.01, 1.05)	0.009
PSA & PPB interaction	357	34	0.999 (0.998, 1.000)	0.177	0.999 (0.998, 1.000)	0.054
Highest Gleason score
6	208	2	1 (Ref)	—	1 (Ref)	—
7	121	17	15.24 (3.52, 65.99)	<0.001	9.70 (2.17, 43.37)	0.003
8–10	28	15	67.60 (15.45, 295.75)	<0.001	25.01 (5.08, 123.14)	<0.001
AJCC clinical tumor category
T1c	295	19	1 (Ref)	—	1 (Ref)	—
T2-3	62	15	3.77 (1.91, 7.42)	<0.001	1.49 (0.72, 3.08)	0.283
Type of nerve sparing RP
BNS	187	3	0.043 (0.011, 0.173)	<0.001	0.407 (0.064, 2.589)	0.341
UNS	151	25	0.473 (0.193, 1.156)	0.101	1.242 (0.355, 4.342)	0.734
Non-NS	19	6	1 (Ref)	—	1 (Ref)	—

HR: hazard ratio; AHR: adjusted hazard ratio; PSA: prostate-specific antigen; PPB: percentage of positive prostate biopsies; AJCC: American Joint Commission on Cancer; RP: radical prostatectomy; BNS: bilateral nerve sparing; UNS: unilateral nerve sparing; Non-NS: non-nerve sparing.